17 Result(s)

Article

Monoclonal antibody therapy in multiple myeloma

The therapeutic landscape of multiple myeloma (MM) has evolved spectacularly over the past decade with the discovery and validation of proteasome inhibitors and immunomodulatory agents as highly active agents,...

C Touzeau, P Moreau, C Dumontet in Leukemia (2017)

Article

Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case–control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium

A Martino, D Campa, G Buda, J Sainz, R García-Sanz, K Jamroziak, R M Reis… in Leukemia (2012)

Article

Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan

High-dose melphalan (HDM) is an essential component in the treatment of patients with multiple myeloma (MM). Few data are available regarding genetic polymorphisms associated with patient outcome or toxicity i...

C Dumontet, S Landi, T Reiman, T Perry, A Plesa, I Bellini… in Bone Marrow Transplantation (2010)

Article

A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells

The zinc-finger protein A20/TNFAIP3, an inhibitor of nuclear factor-κB (NF-κB) activation, has been shown to protect MCF-7 breast carcinoma cells from TNFα-induced apoptosis. As estrogen receptor (ER) status is a...

J A Vendrell, S Ghayad, S Ben-Larbi, C Dumontet, N Mechti, P A Cohen in Oncogene (2007)

Article

Rituximab in CD20 positive multiple myeloma

P Moreau, L Voillat, L Benboukher, C Mathiot, C Dumontet, N Robillard… in Leukemia (2007)

Article

Autoimmune thrombocytopenic purpura after autologous stem cell transplantation

The pathogenesis of thrombocytopenia occurring after autologous stem cell transplantation (ASCT) remains unclear. Six cases of classical peripheral thrombocytopenia that developed after ASCT for non-Hodgkin's ...

O Hequet, G Salles, N Ketterer, D Espinouse, C Dumontet… in Bone Marrow Transplantation (2003)

Article

Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma

High-dose melphalan (HDM) has been adopted as standard therapy in the treatment of multiple myeloma. This treatment is associated with non-selective cytotoxicity, causing oral mucositis as the major non-hemato...

C Thieblemont, C Dumontet, H Saad, N Roch, F Bouafia… in Bone Marrow Transplantation (2002)

Article

Identification and validation of seven genes, as potential markers, for the differential diagnosis of small B cell lymphomas (small lymphocytic lymphoma, marginal zone B cell lymphoma and mantle cell lymphoma) by cDNA macroarrays analysis

C Thieblemont, K Chettab, P Felman, E Callet-Bauchu, A Traverse-Glehen… in Leukemia (2002)

Article

Epileptic seizures after autologous peripheral blood progenitor infusion in a patient treated with high-dose chemotherapy for myeloma

Bone Marrow Transplantation (2002) 29, 544. doi:10.1038/sj.bmt.1703383

O Hequet, C Dumontet, A El Jaafari-Corbin, G Salles… in Bone Marrow Transplantation (2002)

Article

Nucleoside analogues: mechanisms of drug resistance and reversal strategies

Nucleoside analogues (NA) are essential components of AML induction therapy (cytosine arabinoside), effective treatments of lymphoproliferative disorders (fludarabine, cladribine) and are also used in the trea...

CM Galmarini, JR Mackey, C Dumontet in Leukemia (2001)

Article

Late autologous transplantation in chronic myelogenous leukemia with peripheral blood progenitor cells mobilized by G-CSF and interferon-α

In chronic myelogenous leukemia (CML), autologous stem cell transplantation could be a promising new approach for patients with no cytogenetic response after interferon α (IFN-α) therapy. We report data on 28 ...

M Michallet, A Thiébaut, I Philip, C Charrin, C Vigouroux, X Thomas, K Bilger… in Leukemia (2000)

Article

A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors

Patients with nhl and two or three factors of the international prognostic index (ipi) have a poor prognosis. we performed a prospective trial of intensive induction therapy followed with high-dose consolidati...

C Dumontet, C Thieblemont, D Espinouse, F Bouafia, O Hequet, G Salles… in Leukemia (2000)

Article

Toxicities after peripheral blood progenitor cell transplantation for lymphoid malignancies: analysis of 300 cases in a single institution

Two hundred and seventy-seven consecutive patients with non-Hodgkin’s lymphoma (n = 207), Hodgkin’s disease (n = 27) and multiple myeloma (n = 43) were intensified from October 1989 until April 1997 and received ...

N Ketterer, A Sonet, C Dumontet, I Moullet, C Thieblemont… in Bone Marrow Transplantation (1999)

Article

Profiles and prognostic values of LDH isoenzymes in patients with non-Hodgkin’s lymphoma

Serum lactic dehydrogenase (LDH) is an important prognostic factor in patients with non-Hodgkin’s lymphoma (NHL). We have examined the LDH isoenzyme content in serum and CSF of patients with NHL, at diagnosis ...

C Dumontet, J Drai, J Bienvenu, E Neidhardt Berard, C Thieblemont, F Bouafia… in Leukemia (1999)

Article

Mantle cell lymphoma: a retrospective study of 121 cases

Mantle cell lymphoma (MCL) patients represent a difficult problem, sometimes to establish the diagnosis but mostly because of their refractoriness to standard lymphoma treatments. Which treatments to apply and...

H Samaha, C Dumontet, N Ketterer, I Moullet, C Thieblemont, F Bouafia… in Leukemia (1998)

Article

Reduced progression-free survival in elderly patients receiving intensification with autologous peripheral blood stem cell reinfusion for multiple myeloma

Between 1990 and 1997, 55 patients with high risk multiple myeloma underwent high-dose therapy with peripheral blood stem cell transplantation. Intensification consisted of high-dose L-PAM in 54 patients, and ...

C Dumontet, N Ketterer, D Espinouse, EM Neidhardt, I Moullet… in Bone Marrow Transplantation (1998)